BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Tuesday, March 17, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 28, 2020
View Archived Issues
Just add fever
Read More
Tyme advancing oral synthetic bile acid TYME-19 into clinic for COVID-19
Read More
STING agonist JNJ-67544412 shows antitumor activity in syngeneic tumor models
Read More
Synthetic synaptic protein restores neuronal connections
Read More
CKI-alpha/delta inhibitors disclosed by Bayer, Dana-Farber and The Broad Institute
Read More
Novartis discovers deltaF508 mutant CFTR correctors
Read More
New neurotensin receptor type 2 agonists patented by Socpra Sciences Sante et Humaines SEC
Read More
Medibiofarma identifies new prostanoid EP2 and/or EP4 receptor ligands
Read More
ATSO Corp, Cas Biotechnology present antisense oligonucleotides against GST proteins
Read More
Interim data from phase I study of 4-1BB antibody ATOR-1017 in advanced cancer
Read More
European conditional marketing authorization for Blenrep in relapsed and refractory multiple myeloma
Read More
ViiV begins first-in-human study with GSK-3739937 for HIV
Read More
Ocellaris opens enrollment in phase Ib/IIa study of OC-001 in locally advanced or metastatic cancers
Read More
UCB studies dapirolizumab pegol in phase III for moderate to severely active SLE
Read More
PRAK-3202 generates immune response against SARS-Cov-2 antigens in mice
Read More
Limited effect on HBsAg seen with JNJ-6379 regimens in phase II HBV study
Read More
Lilly begins phase II study of LY-3471851 for SLE
Read More
GNE-565: a Nav1.7 inhibitor with oral activity in a mouse model of Nav.17-associated pain
Read More
New phase IIa study evaluates AMT-101 in ulcerative colitis
Read More
